Does lymphovascular invasion trump POLE mutation in early-stage uterine cancer adjuvant therapy decisions?
Would you offer brachytherapy?
Answer from: Radiation Oncologist at Community Practice
In the current ESGO guidelines, stage I and II POLE types are always low risk, irrespective of substantial LVSI, with a predicted risk of recurrence being less than 10 percent, and favoring observation. That being said, in practice, I do offer brachytherapy, as I feel it is a low morbidity procedure...
Comments
Radiation Oncologist at Allegheny Health Network In PORTEC-4a, the recurrence risk in the observed ...
Radiation Oncologist at Varian Medical Systems/Allegheny health network PORTEC 4a didn’t allow the above patient to ...
In PORTEC-4a, the recurrence risk in the observed ...
PORTEC 4a didn’t allow the above patient to ...